Gemfrac Injection contains Teriparatide 600 mcg, a recombinant form of parathyroid hormone used primarily in the treatment of osteoporosis. Teriparatide acts as an anabolic agent, stimulating new bone formation by activating osteoblasts, thereby increasing bone mineral density and reducing the risk of fractures in patients with severe osteoporosis, particularly postmenopausal women and men at high risk for fractures. It is indicated for patients with a history of osteoporotic fractures or those who have failed or are intolerant to other osteoporosis therapies. Gemfrac Injection is administered via subcutaneous injection, typically once daily, under the guidance of a healthcare professional. Treatment duration is generally limited to 18-24 months due to concerns regarding long-term safety. Common adverse effects may include nausea, dizziness, leg cramps, and injection site reactions. It is contraindicated in patients with hypercalcemia, bone malignancies, or metabolic bone diseases other than osteoporosis. Regular monitoring of serum calcium levels and bone density is recommended during therapy. Gemfrac Injection should be used with caution in patients with renal impairment or a history of skeletal radiation. Proper patient education on administration technique and adherence to prescribed dosing is essential to optimize therapeutic outcomes.